Troponin limit of detection plus cardiac risk stratification scores to rule out acute myocardial infarction and 30-day major adverse cardiac events in ED patients

Mitchell D. Datlow, Kelly M. Gray, Adriel Watts, Deborah B. Diercks, Bryn Mumma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

When screening for acute myocardial infarction (AMI), troponin levels below the 99th percentile, including those below the limit of detection (LOD), are considered normal. We hypothesized that a low-risk HEART score (0-3) or ACS Pretest Probability Assessment <2% plus a single troponin below the LOD would rule out both AMI and 30-day major adverse cardiac events (MACE). We studied all patients who presented to a single academic emergency department and received a troponin I (Siemens Ultra Troponin I) from September 1, 2013, to November 13, 2013 (n=888). Demographic and clinical data were abstracted from the electronic medical record. Primary outcome was a final encounter diagnosis of myocardial infarction. Secondary outcome was 30-day MACE, defined as composite of myocardial infarction, revascularization, or death from a cardiac or uncertain etiology. Sensitivities of low-risk HEART score and ACS Pretest Probability <2% alone were 98% (95% confidence interval [CI], 89%-100%) and 96% (95% CI, 86%-100%) for AMI and 94% (95% CI, 86%-98%) and 95% (95% CI, 88%-99%), respectively, for 30-day MACE. When combined with troponin below the LOD, sensitivity for AMI was 100% (95% CI, 93%-100%; difference 2%; 95% CI, -2% to 6%) for low-risk HEART Score and 100% (95% CI, 93%-100%; difference 4%; 95% CI, -1.5% to 10%) for ACS Pretest Probability <2%. When combined with troponin below the LOD, sensitivity for 30-day MACE was 100% (95% CI, 95%-100%; difference 6%; 95% CI, 1%-12%) for low-risk HEART Score and 100% (95% CI, 95%-100%; difference 5%; 95% CI, 0.2%-10%) for ACS Pretest Probability <2%. Addition of a single troponin below the LOD to these scores improves sensitivity for 30-day MACE.

Original languageEnglish (US)
Pages (from-to)142-146
Number of pages5
JournalCritical Pathways in Cardiology
Volume16
Issue number4
DOIs
StatePublished - Jan 1 2017

Fingerprint

Troponin
Limit of Detection
Myocardial Infarction
Confidence Intervals
Troponin I
Myocardial Revascularization
Electronic Health Records
Hospital Emergency Service
Demography

Keywords

  • Cardiac risk stratification
  • Myocardial infarction
  • Troponin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Troponin limit of detection plus cardiac risk stratification scores to rule out acute myocardial infarction and 30-day major adverse cardiac events in ED patients. / Datlow, Mitchell D.; Gray, Kelly M.; Watts, Adriel; Diercks, Deborah B.; Mumma, Bryn.

In: Critical Pathways in Cardiology, Vol. 16, No. 4, 01.01.2017, p. 142-146.

Research output: Contribution to journalArticle

@article{44267de0d18941fa9943873c7bb5bedc,
title = "Troponin limit of detection plus cardiac risk stratification scores to rule out acute myocardial infarction and 30-day major adverse cardiac events in ED patients",
abstract = "When screening for acute myocardial infarction (AMI), troponin levels below the 99th percentile, including those below the limit of detection (LOD), are considered normal. We hypothesized that a low-risk HEART score (0-3) or ACS Pretest Probability Assessment <2{\%} plus a single troponin below the LOD would rule out both AMI and 30-day major adverse cardiac events (MACE). We studied all patients who presented to a single academic emergency department and received a troponin I (Siemens Ultra Troponin I) from September 1, 2013, to November 13, 2013 (n=888). Demographic and clinical data were abstracted from the electronic medical record. Primary outcome was a final encounter diagnosis of myocardial infarction. Secondary outcome was 30-day MACE, defined as composite of myocardial infarction, revascularization, or death from a cardiac or uncertain etiology. Sensitivities of low-risk HEART score and ACS Pretest Probability <2{\%} alone were 98{\%} (95{\%} confidence interval [CI], 89{\%}-100{\%}) and 96{\%} (95{\%} CI, 86{\%}-100{\%}) for AMI and 94{\%} (95{\%} CI, 86{\%}-98{\%}) and 95{\%} (95{\%} CI, 88{\%}-99{\%}), respectively, for 30-day MACE. When combined with troponin below the LOD, sensitivity for AMI was 100{\%} (95{\%} CI, 93{\%}-100{\%}; difference 2{\%}; 95{\%} CI, -2{\%} to 6{\%}) for low-risk HEART Score and 100{\%} (95{\%} CI, 93{\%}-100{\%}; difference 4{\%}; 95{\%} CI, -1.5{\%} to 10{\%}) for ACS Pretest Probability <2{\%}. When combined with troponin below the LOD, sensitivity for 30-day MACE was 100{\%} (95{\%} CI, 95{\%}-100{\%}; difference 6{\%}; 95{\%} CI, 1{\%}-12{\%}) for low-risk HEART Score and 100{\%} (95{\%} CI, 95{\%}-100{\%}; difference 5{\%}; 95{\%} CI, 0.2{\%}-10{\%}) for ACS Pretest Probability <2{\%}. Addition of a single troponin below the LOD to these scores improves sensitivity for 30-day MACE.",
keywords = "Cardiac risk stratification, Myocardial infarction, Troponin",
author = "Datlow, {Mitchell D.} and Gray, {Kelly M.} and Adriel Watts and Diercks, {Deborah B.} and Bryn Mumma",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/HPC.0000000000000129",
language = "English (US)",
volume = "16",
pages = "142--146",
journal = "Critical Pathways in Cardiology",
issn = "1535-282X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Troponin limit of detection plus cardiac risk stratification scores to rule out acute myocardial infarction and 30-day major adverse cardiac events in ED patients

AU - Datlow, Mitchell D.

AU - Gray, Kelly M.

AU - Watts, Adriel

AU - Diercks, Deborah B.

AU - Mumma, Bryn

PY - 2017/1/1

Y1 - 2017/1/1

N2 - When screening for acute myocardial infarction (AMI), troponin levels below the 99th percentile, including those below the limit of detection (LOD), are considered normal. We hypothesized that a low-risk HEART score (0-3) or ACS Pretest Probability Assessment <2% plus a single troponin below the LOD would rule out both AMI and 30-day major adverse cardiac events (MACE). We studied all patients who presented to a single academic emergency department and received a troponin I (Siemens Ultra Troponin I) from September 1, 2013, to November 13, 2013 (n=888). Demographic and clinical data were abstracted from the electronic medical record. Primary outcome was a final encounter diagnosis of myocardial infarction. Secondary outcome was 30-day MACE, defined as composite of myocardial infarction, revascularization, or death from a cardiac or uncertain etiology. Sensitivities of low-risk HEART score and ACS Pretest Probability <2% alone were 98% (95% confidence interval [CI], 89%-100%) and 96% (95% CI, 86%-100%) for AMI and 94% (95% CI, 86%-98%) and 95% (95% CI, 88%-99%), respectively, for 30-day MACE. When combined with troponin below the LOD, sensitivity for AMI was 100% (95% CI, 93%-100%; difference 2%; 95% CI, -2% to 6%) for low-risk HEART Score and 100% (95% CI, 93%-100%; difference 4%; 95% CI, -1.5% to 10%) for ACS Pretest Probability <2%. When combined with troponin below the LOD, sensitivity for 30-day MACE was 100% (95% CI, 95%-100%; difference 6%; 95% CI, 1%-12%) for low-risk HEART Score and 100% (95% CI, 95%-100%; difference 5%; 95% CI, 0.2%-10%) for ACS Pretest Probability <2%. Addition of a single troponin below the LOD to these scores improves sensitivity for 30-day MACE.

AB - When screening for acute myocardial infarction (AMI), troponin levels below the 99th percentile, including those below the limit of detection (LOD), are considered normal. We hypothesized that a low-risk HEART score (0-3) or ACS Pretest Probability Assessment <2% plus a single troponin below the LOD would rule out both AMI and 30-day major adverse cardiac events (MACE). We studied all patients who presented to a single academic emergency department and received a troponin I (Siemens Ultra Troponin I) from September 1, 2013, to November 13, 2013 (n=888). Demographic and clinical data were abstracted from the electronic medical record. Primary outcome was a final encounter diagnosis of myocardial infarction. Secondary outcome was 30-day MACE, defined as composite of myocardial infarction, revascularization, or death from a cardiac or uncertain etiology. Sensitivities of low-risk HEART score and ACS Pretest Probability <2% alone were 98% (95% confidence interval [CI], 89%-100%) and 96% (95% CI, 86%-100%) for AMI and 94% (95% CI, 86%-98%) and 95% (95% CI, 88%-99%), respectively, for 30-day MACE. When combined with troponin below the LOD, sensitivity for AMI was 100% (95% CI, 93%-100%; difference 2%; 95% CI, -2% to 6%) for low-risk HEART Score and 100% (95% CI, 93%-100%; difference 4%; 95% CI, -1.5% to 10%) for ACS Pretest Probability <2%. When combined with troponin below the LOD, sensitivity for 30-day MACE was 100% (95% CI, 95%-100%; difference 6%; 95% CI, 1%-12%) for low-risk HEART Score and 100% (95% CI, 95%-100%; difference 5%; 95% CI, 0.2%-10%) for ACS Pretest Probability <2%. Addition of a single troponin below the LOD to these scores improves sensitivity for 30-day MACE.

KW - Cardiac risk stratification

KW - Myocardial infarction

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=85045553212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045553212&partnerID=8YFLogxK

U2 - 10.1097/HPC.0000000000000129

DO - 10.1097/HPC.0000000000000129

M3 - Article

VL - 16

SP - 142

EP - 146

JO - Critical Pathways in Cardiology

JF - Critical Pathways in Cardiology

SN - 1535-282X

IS - 4

ER -